Fisk Ryan reported grant involving 170,692 derivative units of ADARx Pharmaceuticals, Inc. at $0.00 for $0 on Sep 24, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
CFO and CBO
CFO and CBO
Filed Sep 28, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
170,692Employee Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
170,692Direct
Trade date
Sep 24, 2026Grant
Filed
Sep 28, 2026, 4:30 PM ET4-day reporting delay
Accession
0002151480-26-000004Code A · Transaction 230412
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ADRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ADRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 5, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: 1/4th of the total shares vest and become exercisable on September 24, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.